No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: A randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT trial)

Chinese Medical Journal

Volumn 123, Issue 20, 2010, Pages 2858-2864

  Zhang, Hai Tao ^a   Jia, Zhen Hua ^b   Zhang, Jian ^b   Ye, Zan Kai ^a   Yang, Wei Xian ^a   Tian, Yue Qin ^a   Jia, Xuan ^c   Li, Wei ^c   Wu, Yi Ling ^b   Yang, Yue Jin ^a  

^a FUWAI HOSPITAL   (China)

^b The Integration of Traditional and Western Medical Research Academy of Hebei Province   (China)

^c National Center for Cardiovascular Diseases   (China)

Author keywords

Acute myocardial infarction; No reflow; Percutaneous coronary intervention; Tongxinluo

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HERBACEOUS AGENT; PLACEBO; TONGXINLUO; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BALLOON DILATATION; CHINESE MEDICINE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ACUTE DISEASE; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; HEART INFARCTION; MIDDLE AGED; PATHOPHYSIOLOGY;

ACUTE DISEASE; AGED; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; MYOCARDIAL INFARCTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79952277044     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.20.021     Document Type: Article

References (33)

1. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-228.
2. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765-772.
3. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002; 39: 591-597.
4. Abbate A, Kontos MC, Biondi-Zoccai GG. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. Eur Heart J 2008; 29, 1795-1797.
5. Yang YJ, Zhao JL, Jing ZC, Wu YJ, You SJ, Yang WX, et al. Beneficial effects of Tong-xin-luo (herb) on myocardial no-reflow after acute myocardial infarction and reperfusion: experiment of mini-swine model. Natl Med J China (Chin) 2005; 85: 883-888.
6. Yang YJ, Zhao JJ, Meng L. Effect of tongxinluo ultramicro-pulverization on myocardial post-reperfusion no-reflow in mini-swine model of acute myocardial infarction. Chin J Interg Med (Chin) 2006; 26: 49-53.
7. You SJ, Yang YJ, Chen KJ, Gao RL, Wu YJ, Zhang J, et al. The protective effects of Tong-xin-luo on myocardium and microvasculature after reperfusion in acute myocardial infarction. Chin J Cardiol (Chin) 2005; 33: 433-437.
8. Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001; 38: 472-477.
9. Kirma C, Izgi A, Dundar C, Tanalp AC, Oduncu V, Aung SM, et al. Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ J 2008; 72: 716-721.
10. Tartan Z, Ozer N, Uyarel H, Akgul O, Gul M, Cetin M, et al. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction. Nutr Metab Cardiovasc Dis 2008; 18: 441-447.
11. Zhao JL, Yang YJ, Cui CJ, You SJ, Gao RL. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol 2006; 149: 243-249.
12. Zhao JL, Yang YJ, Jing ZC, Wu YJ, You SJ, Yang WX, et al. Beneficial effects of fosinopril on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Chin J Cardiol (Chin) 2005; 33: 638-642.
13. Zhao JL, Yang YJ, Wu YJ, Jing ZC, You SJ, Yang WX, et al. No-reflow after acute myocardial infarction and reperfusion and protective effects of valsartan on myocardium in a mini-swine model. Chin Annal Clin Rehabilit (Chin) 2005; 9: 75-81.
14. Desmet WJ, Mesotten LV, Maes AF, Heidbuchel HP, Mortelmans LA, Van de Werf FJ. Relation between different methods for analysing ST segment deviation and infarct size as assessed by positron emission tomography. Heart 2004; 90: 887-892.
15. Zalewski J, Zmudka K, Musialek P, Zajdel W, Pieniazek P, Kadzielski A, et al. Detection of microvascular injury by evaluating epicardial blood flow in early reperfusion following primary angioplasty. Int J Cardiol 2004; 96: 389-396.
16. Kelly RV, Cohen MG, Runge MS, Stouffer GA. The no-reflow phenomenon in coronary arteries. J Thromb Haemost 2004; 2: 1903-1907.
17. Kang S, Yang YJ, Wu YL, Chen YT, Li L, Tian Y. Myocardium and microvessel endothelium apoptosis at day 7 following reperfused acute myocardial infarction. Microvasc Res 2010; 79: 70-79.
18. Kang S, Yang YJ, Wang QZ, Li Y, Tian Y, Cheng YT. Expressions of eNOS3 and Ve-cadherin in microvascular endothelium at 7-day of reperfused acute myocardial infarction. Cardiovasc Hematol Disord Drug Targets 2009; 9: 107-117.
19. Niccoli G, Giubilato S, Russo E, Spaziani C, Leo A, Porto I, et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 2008; 29: 1843-1850.
20. Popma JJ, Cox N, Hauptmann KE, Reifart N, Virmani R, Emira K, et al. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. Catheter Cardiovasc Interv 2002; 57: 125-134.
21. Nakamura T, Kubo N, Seki Y, Ikeda N, Ishida T, Funayama H, et al. Effects of a distal protection device during primary stenting in patients with acute anterior myocardial infarction. Circ J 2004; 68: 763-768.
22. Hofmann R, Kypta A, Kerschner K, Grund M, Steinwender C, Leisch F. Thrombus aspiration prior to primary angioplasty in acute myocardial infarction: estimation of rescued myocardial tissue by return of ST-segment elevation. Clin Cardiol 2004; 27: 451-454.
23. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary steting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903.
24. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. J Am Coll Cardiol 2004; 43: 276-283.
25. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193-1199
26. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no-reflow phenimenon". Catheter Cardiovasc Interv 2000; 51: 27-31.
27. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-2159.
28. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660.
29. Lee CH, Wong HB, Tan HC, Zhang JJ, Teo SG, Ong HY, et al. Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1328 patient registry. J Interv Cardiol 2005; 18: 261-266.
30. Zhang HT, Yang YJ, Wu YL, Cheng YT, Kang S, Zhao JL, et al. Effects of tongxinluo on mini-swine vascular endothelial integrity and myocardial no-reflow in early reperfusion of acute myocardial infarction. Natl Med J China (Chin) 2009; 89: 1421-1425.
31. Cheng YT, Yang YJ, Zhang HT, Qian HY, Zhao JL, Meng XM, et al. Pretreatment with Tongxinluo protects porcine myocardium from ischemia/reperfusion injury through a nitric oxide related mechanism. Chin Med J 2009; 122: 1529-1538.
32. Zhang HT, Yang YJ, Cheng YT, Kang S, Zhao JL, Meng L, et al. Effect of Tongxinluo on mini-swine cytokines and myocardial no-reflow in early reperfusion of acute myocardial infarction. Chin J Interg Med (Chin) 2009; 29: 821-824.
33. Duan L, Meng L, Tian Y, Yang YJ, Zhang HT, Cheng YT, et al. Protective effect of Tongxinluo on mini-swine model of acute myocardial infarction and reperfusion damaged by oxidative stress. Chin J Pathol Physiol (Chin) 2010; 26: 430-434.